Login Register Cart 0
Generic placeholder image

Cardiovascular & Hematological Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5257
ISSN (Online): 1875-6182

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

The Role of Human Platelet-rich Plasma to Enhance the Differentiation of Adipose-derived Mesenchymal Stem Cells into Cardiomyocyte: An Experimental Study

Author(s): I.Gde Rurus Suryawan, Andrianto*, Arifta Devi Anggaraeni, Arisya Agita and Ricardo Adrian Nugraha

Volume 21, Issue 3, 2023

Published on: 26 July, 2022

Page: [156 - 166] Pages: 11

DOI: 10.2174/1871525720666220510211116

Price: $65

Abstract

Background: Several studies have shown that adipose-derived mesenchymal stem cells (AMSCs) can differentiate into mesenchymal lineages, including cardiac cell types, but complete differentiation into cardiomyocytes is challenging. Unfortunately, the optimal method to maximize AMSCs differentiation has not yet been established. Platelet-rich plasma (PRP), which contains rich growth factors, is believed to stimulate stem cell proliferation and differentiation in the context of cardiac tissue regeneration.

Objective: This study aimed to analyze the effect of PRP administration to enhance the differentiation of AMSCs into cardiomyocytes.

Methods: This study used a randomized post-test-only controlled group design. AMSCs were isolated from adipose tissues and cultured for 4 passages. The samples were divided into 3 groups, a negative control group (α-MEM), a positive control group (differentiation medium), and a treatment group (PRP). The assessment of GATA-4 expression was conducted using flow cytometry on day-5. The assessment of troponin expression was conducted using immunocytochemistry on day- 10. Data analysis was conducted using T-test and One-Way ANOVA.

Results: Flowcytometry of GATA-4 expression revealed a significant improvement in PRP group compared to negative and positive control group (67.04 ± 4.49 vs. 58.15 ± 1.23 p < 0.05; 67.04 ± 4.49 vs. 52.96 ± 2.02 p < 0.05). This was supported by the results of immunocytochemistry on troponin expression, which revealed significant improvement in the PRP group compared to negative and positive controls (38.13 ± 5.2 vs. 10.73 ± 2.39 p < 0.05; 38.13 ± 5.2 vs. 26.00 ± 0.4 p < 0.05).

Conclusion: PRP administration in the AMSCs culture could significantly improve the differentiation of AMSCs into cardiomyocytes measured by GATA-4 and troponin expressions. This was concordant with our hypothesis, which stated that there was an effect of PRP administration on AMSCs differentiation into cardiomyocytes.

Keywords: Adipocyte-derived mesenchymal stem cells, cardiac troponin-T, GATA-4, platelet rich plasma, growth factor, cardiac regeneration.

« Previous Next »
[1]
World Health Organisation. Global Status Report on Noncommunicable Disease; WHO Press, 2014. Available from: https://ifa.ngo/publication/health/global-status-report-onnoncommunicable-diseases/
[2]
Talman, V.; Kivelä, R. Cardiomyocyte-endothelial cell interactions in cardiac remodeling and regeneration. Front. Cardiovasc. Med., 2018, 5, 101.
[http://dx.doi.org/10.3389/fcvm.2018.00101]
[3]
Sid-Otmane, C.; Perrault, L.P.; Ly, H.Q. Mesenchymal stem cell mediates cardiac repair through autocrine, paracrine and endocrine axes. J. Transl. Med., 2020, 18(1), 336.
[http://dx.doi.org/10.1186/s12967-020-02504-8] [PMID: 32873307]
[4]
Müller, P.; Lemcke, H.; David, R. Stem cell therapy in heart diseases - Cell types, mechanisms and improvement strategies. Cell. Physiol. Biochem., 2018, 48(6), 2607-2655.
[http://dx.doi.org/10.1159/000492704] [PMID: 30121644]
[5]
Ye, J.; Yeghiazarians, Y. Cardiac stem cell therapy: Have we put too much hype in which cell type to use? Heart Fail. Rev., 2015, 20(5), 613-619.
[http://dx.doi.org/10.1007/s10741-015-9494-7] [PMID: 26024953]
[6]
Sun, X.; Li, H.; Zhu, Y.; Xu, P.; Zuo, Q.; Li, B.; Gu, X. 5-Azacytidine-induced cardiomyocyte differentiation of very small embryonic-like stem cells. Stem Cells Int., 2020, 2020, 5162350.
[http://dx.doi.org/10.1155/2020/5162350]
[7]
Song, N.; Scholtemeijer, M.; Shah, K. Mesenchymal stem cell immunomodulation: Mechanisms and therapeutic potential. Trends Pharmacol. Sci., 2020, 41(9), 653-664.
[http://dx.doi.org/10.1016/j.tips.2020.06.009] [PMID: 32709406]
[8]
Sousa, B.R.; Parreira, R.C.; Fonseca, E.A.; Amaya, M.J.; Tonelli, F.M.; Lacerda, S.M.; Lalwani, P.; Santos, A.K.; Gomes, K.N.; Ulrich, H.; Kihara, A.H.; Resende, R.R. Human adult stem cells from diverse origins: An overview from multiparametric immunophenotyping to clinical applications. Cytometry A, 2014, 85(1), 43-77.
[http://dx.doi.org/10.1002/cyto.a.22402] [PMID: 24700575]
[9]
Everts, P.; Onishi, K.; Jayaram, P.; Lana, J.F.; Mautner, K. Plateletrich plasma: New performance understandings and therapeutic considerations in 2020. Int. J. Mol. Sci., 2020, 21(20), 7794.
[http://dx.doi.org/10.3390/ijms21207794] [PMID: 33096812]
[10]
Magalon, J.; Chateau, A.L.; Bertrand, B.; Louis, M.L.; Silvestre, A.; Giraudo, L.; Veran, J.; Sabatier, F. DEPA classification: A proposal for standardising PRP use and a retrospective application of available devices. BMJ Open Sport Exerc. Med., 2016, 2(1), e000060.
[http://dx.doi.org/10.1136/bmjsem-2015-000060]
[11]
Wamaitha, S.E.; Grybel, K.J.; Alanis-Lobato, G.; Gerri, C.; Ogushi, S.; McCarthy, A.; Mahadevaiah, S.K.; Healy, L.; Lea, R.A.; Molina-Arcas, M.; Devito, L.G.; Elder, K.; Snell, P.; Christie, L.; Downward, J.; Turner, J.M.A.; Niakan, K.K. IGF1-mediated human embryonic stem cell self-renewal recapitulates the embryonic niche. Nat. Commun., 2020, 11(1), 764.
[http://dx.doi.org/10.1038/s41467-020-14629-x] [PMID: 32034154]
[12]
Liu, Y.; Song, J.W.; Lin, J.Y.; Miao, R.; Zhong, J.C. Roles of microRNA-122 in cardiovascular fibrosis and related diseases. Cardiovasc. Toxicol., 2020, 20(5), 463-473.
[http://dx.doi.org/10.1007/s12012-020-09603-4] [PMID: 32856216]
[13]
Borden, A.; Kurian, J.; Nickoloff, E.; Yang, Y.; Troupes, C.D.; Ibetti, J.; Lucchese, A.M.; Gao, E.; Mohsin, S.; Koch, W.J.; Houser, S.R.; Kishore, R.; Khan, M. Transient introduction of miR-294 in the heart promotes cardiomyocyte cell cycle reentry after injury. Circ. Res., 2019, 125(1), 14-25.
[http://dx.doi.org/10.1161/CIRCRESAHA.118.314223] [PMID: 30964391]
[14]
Wang, D.; Li, T.; Xu, Y.; Yang, X.; He, M.; Zhang, Z.; Wu, W.; Yan, Y. Platelet-rich plasma alleviates myocardial ischemia reperfusion injury in rats. Nan Fang Yi Ke Da Xue Xue Bao, 2021, 41(5), 775-782.
[http://dx.doi.org/10.12122/j.issn.1673-4254.2021.05.20] [PMID: 34134967]
[15]
Gallo, I.; Sáenz, A.; Arévalo, A.; Roussel, S.; Pérez-Moreiras, I.; Artiñano, E.; Martínez-Peñuela, A.; Esquide, J.; Aspiroz, A.; Camacho, I. Effect of autologous platelet-rich plasma on heart infarction in sheep. Arch. Cardiol. Mex., 2013, 83(3), 154-158.
[http://dx.doi.org/10.1016/j.acmx.2013.04.011] [PMID: 23896065]

Rights & Permissions Print Cite
Article Metrics
3
© 2024 Bentham Science Publishers | Privacy Policy